Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hematologic”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT05160584
What this trial is testing

Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium 300
Testing effectiveness (Phase 2)Study completedNCT05774184
What this trial is testing

CDX-0159 in Patients With Eosinophilic Esophagitis

Who this might be right for
Eosinophilic Esophagitis
Celldex Therapeutics 86
Very early researchLooking for participantsNCT06385652
What this trial is testing

PET Imaging Study of 68Ga-NB381 in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Peking University First Hospital 30
Early research (Phase 1)Looking for participantsNCT05945849
What this trial is testing

CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML

Who this might be right for
Leukemia, Myeloid, Acute
University of Pennsylvania 16
Testing effectiveness (Phase 2)Study completedNCT04992949
What this trial is testing

Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Who this might be right for
Acute Myeloid LeukemiaMyeloproliferative Syndrome
French Innovative Leukemia Organisation 42
Testing effectiveness (Phase 2)WithdrawnNCT06085638
What this trial is testing

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Who this might be right for
Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Very early researchUnknownNCT04186052
What this trial is testing

Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Not applicableNot Yet RecruitingNCT05440747
What this trial is testing

Treatment Free Remission (TFR) in CML Patients （CML-CP）Study

Who this might be right for
Chronic Myeloid LeukemiaTreatment-free Remission
Guangdong Provincial People's Hospital 203
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07516847
What this trial is testing

Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes (MDS)Anemia
Seug yun Yoon, MD 37
Large-scale testing (Phase 3)Ended earlyNCT00109538
What this trial is testing

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicMyelodysplasia+1 more
Merck Sharp & Dohme LLC 47
Not applicableStudy completedNCT07249138
What this trial is testing

Impact of Congenital Heart Disease on the Prognosis of Childhood Hematological Neoplasms: A Multicenter Cohort Study

Who this might be right for
Congenital Heart Disease (CHD)Hematologic Malignancy
Children's Hospital of Fudan University 800
Testing effectiveness (Phase 2)Active Not RecruitingNCT05656248
What this trial is testing

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

Who this might be right for
Myeloid Neoplasm
St. Jude Children's Research Hospital 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT06098326
What this trial is testing

CyFluATG in Lower Risk MDS

Who this might be right for
Myelodysplastic Syndromes
Asan Medical Center 30
Not applicableUnknownNCT06476535
What this trial is testing

Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy

Who this might be right for
Myeloproliferative NeoplasmInflammatory Disease
University Hospital, Brest 100
Early research (Phase 1)UnknownNCT03840317
What this trial is testing

Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia

Who this might be right for
Acute Lymphocytic Leukemia
Hebei Senlang Biotechnology Inc., Ltd. 20
Testing effectiveness (Phase 2)Study completedNCT01865617
What this trial is testing

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Who this might be right for
CD19-Positive Neoplastic Cells PresentRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic Leukemia+10 more
Fred Hutchinson Cancer Center 204
Large-scale testing (Phase 3)Not Yet RecruitingNCT07735117
What this trial is testing

Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)
Ruijin Hospital 168
Early research (Phase 1)Looking for participantsNCT06854640
What this trial is testing

Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy

Who this might be right for
SepsisCoagulopathy
Bayer 36
Early research (Phase 1)Study completedNCT00047489
What this trial is testing

Study of ABT-751 in Patients With Refractory Hematologic Malignancies

Who this might be right for
Hematological Malignancies
M.D. Anderson Cancer Center 32
Not applicableStudy completedNCT00969891
What this trial is testing

Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Mikkel Krogh-Madsen 23
Next Page